Compare
Emergent BioSolutions Inc. vs Pacira BioSciences, Inc. vs Harmony Biosciences Holdings, Inc. vs Opko Health, Inc.
| Latest fiscal year | Emergent BioSolutions Inc. EBS | Pacira BioSciences, Inc. PCRX | Harmony Biosciences Holdings, Inc. HRMY | Opko Health, Inc. OPK |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $742.90M | $726.41M | $868.45M | $606.88M |
| Revenue growth (YoY) | -28.8% | +3.6% | +21.5% | -14.9% |
| Gross margin | 56.1% (computed) | 79.4% (computed) | 77.2% | 33.9% |
| Operating margin | 13.5% | 2.6% | 24.0% | -19.3% |
| Net margin | 7.1% | 1.0% | 18.3% | -37.2% |
| Net income | $52.60M | $7.03M | $158.69M | -$225.68M |
| EPS (Diluted) | $0.93 | $0.16 | $2.71 | -$0.30 |
| Operating cash flow | $170.60M | $151.99M | $348.20M | -$178.54M |
| Free cash flow | $156.80M | $136.66M | $347.89M | -$190.82M |
| Cash & equivalents | $205.40M | $158.54M | $752.50M | $364.41M |
| Total assets | $1.32B | $1.26B | $1.27B | $1.93B |
| Total liabilities | $796.00M | $571.81M | $401.41M | $663.99M |
| Shareholders' equity | $522.60M | $693.11M | $870.22M | $1.27B |
| Return on year-end equity | 10.1% | 1.0% | 18.2% | -17.8% |
| Shares outstanding | 52.10M | 41.12M | 57.73M | n/a |
Revenue, most recent five fiscal years
| Fiscal year | Emergent BioSolutions Inc. | Pacira BioSciences, Inc. | Harmony Biosciences Holdings, Inc. | Opko Health, Inc. |
|---|---|---|---|---|
| Latest | $742.90M Ended 2025-12-31 | $726.41M Ended 2025-12-31 | $868.45M Ended 2025-12-31 | $606.88M Ended 2025-12-31 |
| 1 year earlier | $1.04B Ended 2024-12-31 | $700.97M Ended 2024-12-31 | $714.73M Ended 2024-12-31 | $713.14M Ended 2024-12-31 |
| 2 years earlier | $1.05B Ended 2023-12-31 | $674.98M Ended 2023-12-31 | $582.02M Ended 2023-12-31 | $863.50M Ended 2023-12-31 |
| 3 years earlier | $1.12B Ended 2022-12-31 | $666.82M Ended 2022-12-31 | $437.86M Ended 2022-12-31 | $1.00B Ended 2022-12-31 |
| 4 years earlier | $1.77B Ended 2021-12-31 | $541.53M Ended 2021-12-31 | $305.44M Ended 2021-12-31 | $1.77B Ended 2021-12-31 |